TRT 'good results' claims: what the evidence actually supports
Quick answer
DHT-derived anabolic steroids are not aromatase substrates, meaning they do not convert to estrogen, which produces a distinct androgenic hormonal profile compared to testosterone alone. This class includes compounds like drostanolone, methenolone, stanozolol, and oxandrolone, most of which are Schedule III controlled substances in the US and are not standard-of-care TRT options. The documented adverse effects include HDL suppression, acceleration of androgenic alopecia in susceptible individuals, and hepatotoxicity for orally active 17-alpha alkylated variants.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @chris_practical actually say?
The creator made a specific argument: DHT derivatives produce a distinct psychological and physical effect, described as feeling "very masculine and ambitious," but come with real costs, specifically hairline recession and worse lipid profiles compared to testosterone alone. He also noted these compounds are nearly impossible to obtain through legitimate TRT clinics, with anavar being a partial exception he immediately dismissed. He then positioned himself as someone who uses these with clients regularly and invited people to DM him for guidance.
That last part is where things get complicated. The clinical observations about DHT derivatives are worth taking seriously. The sales pitch at the end is not a medical service, it's a coaching arrangement, and the distinction matters legally and practically for anyone considering this path.
Does the science back this up?
On the core pharmacology, yes, largely. DHT-derived anabolic steroids, including compounds like stanozolol, masteron (drostanolone), and primobolan (methenolone), do not aromatize to estrogen, which changes the hormonal environment meaningfully. The subjective reports of increased drive and well-being are consistent with what androgen receptor binding patterns would predict, though the evidence here is mostly observational rather than from controlled trials.
The lipid claim is well-supported. DHT derivatives, particularly oral forms, are associated with significant reductions in HDL cholesterol. Hartgens and Kuipers (2004, Sports Medicine) documented that anabolic-androgenic steroids can reduce HDL by 20-70% depending on compound and dose. Oral 17-alpha alkylated compounds hit harder than injectables. The hairline claim is also pharmacologically sound: DHT is the primary driver of androgenic alopecia, and compounds that resist conversion away from DHT, or directly bind androgen receptors in hair follicles, accelerate this process in genetically susceptible individuals (Randall, 2008, Journal of Endocrinology).
What did they get right, and what did they get wrong?
Credit where it is due: the creator did not oversell this. Saying "it's not all rainbows and sunshine" before naming specific risks is more honest than most TikTok content in this category. The framing that these are add-ons rather than replacements, and that access through legitimate clinics is difficult, reflects reality accurately.
What's missing is more significant than what's wrong. There is no mention of cardiovascular risk beyond lipids. DHT derivatives, especially oral ones, carry hepatotoxicity risk for 17-alpha alkylated versions (Dickerman et al., 1995, Chest). There is no discussion of the legal status of most of these compounds in the US, where they are Schedule III controlled substances. And "DM me for safety" is doing a lot of work as a disclaimer for what amounts to advising people on unlicensed drugs. The phrase "cycle safer" in the caption implies harm reduction for illicit use, which is a different conversation than TRT optimization.
What should you actually know?
If you are on testosterone replacement therapy through a licensed provider, adding a DHT derivative is not something most clinics will prescribe, and for reasons that go beyond caution. The risk-benefit math changes significantly when you layer compounds. Lipid deterioration that looks manageable on paper can translate to measurable cardiovascular risk over years, not months.
The subjective "feel" that people describe on DHT derivatives is real in the sense that androgen receptor activity does influence mood, confidence, and drive. But subjective benefit is not a clinical endpoint. Anyone drawn to this approach should at minimum get a full lipid panel, liver enzymes, hematocrit, and blood pressure monitoring if they proceed, and they should do so with a physician who knows what they are taking, not just a DM conversation.
Anavar (oxandrolone) is the one compound in this class with actual clinical trial data, including use in HIV wasting and recovery from burns (Orr and Singh, 2004, Sports Medicine). Even there, lipid effects are real. Nothing in this category is free of trade-offs.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT 'good results' claims: what the evidence actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT 'good results' claims: what the evidence actually supports should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
DHT-derived anabolic steroids are not aromatase substrates, meaning they do not convert to estrogen, which produces a distinct androgenic hormonal profile compared to testosterone alone.
FormBlends verdict
DHT-derived anabolic steroids are not aromatase substrates, meaning they do not convert to estrogen, which produces a distinct androgenic hormonal profile compared to testosterone alone. This class includes compounds like drostanolone, methenolone, stanozolol, and oxandrolone, most of which are Schedule III controlled substances in the US and are not standard-of-care TRT options. The documented adverse effects include HDL suppression, acceleration of androgenic alopecia in susceptible individuals, and hepatotoxicity for orally active 17-alpha alkylated variants.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- DHT-derived anabolic steroids are not aromatase substrates, meaning they do not convert to estrogen, which produces a distinct androgenic hormonal profile compared to testosterone alone. This class includes compounds like drostanolone, methenolone, stanozolol, and oxandrolone, most of which are Schedule III controlled substances in the US and are not standard-of-care TRT options. The documented adverse effects include HDL suppression, acceleration of androgenic alopecia in susceptible individuals, and hepatotoxicity for orally active 17-alpha alkylated variants.
- DHT derivatives do not aromatize to estrogen, which produces a distinct androgenic hormonal environment compared to standard testosterone therapy.
- Hartgens and Kuipers (2004, Sports Medicine) found anabolic-androgenic steroids can reduce HDL cholesterol by 20-70% depending on compound and route of administration.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- DHT derivatives do not aromatize to estrogen, which produces a distinct androgenic hormonal environment compared to standard testosterone therapy.
- Hartgens and Kuipers (2004, Sports Medicine) found anabolic-androgenic steroids can reduce HDL cholesterol by 20-70% depending on compound and route of administration.
- Oral 17-alpha alkylated DHT derivatives carry hepatotoxicity risk in addition to lipid effects, a risk the creator did not mention (Dickerman et al., 1995, Chest).
- Most DHT-derived compounds discussed in this context are Schedule III controlled substances in the US and are not standard TRT clinic prescriptions.
- Oxandrolone (anavar) has the most robust clinical trial data in this compound class, with documented use in muscle wasting, but lipid effects are still present (Orr and Singh, 2004, Sports Medicine).
- Anyone using compounds in this category should monitor a full lipid panel, liver enzymes, hematocrit, and blood pressure, not rely on a DM conversation for safety guidance.
- The subjective well-being effect of DHT derivatives is reported consistently but has not been established in controlled trials as a clinical endpoint separate from general androgen load.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
chris_practical · TikTok creator
12.1K views on this video
Not a bad move, alota good results
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by chris_practical, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.